APA citiranje

Van der Linden, N., Van Olst, S., Nekeman, S., & Uyl‐de Groot, C. (2020). The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands. Diabet Med.

Citação norma Chicago

Van der Linden, N., S. Van Olst, S. Nekeman, and C.A Uyl‐de Groot. "The Cost‐effectiveness of Dapagliflozin Compared to DPP‐4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in the Netherlands." Diabet Med 2020.

MLA citiranje

Van der Linden, N., S. Van Olst, S. Nekeman, and C.A Uyl‐de Groot. "The Cost‐effectiveness of Dapagliflozin Compared to DPP‐4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in the Netherlands." Diabet Med 2020.